ΠΦΥ -Εκπαίδευση > Αποσπάσματα από τον έντυπο & ηλεκτρονικό τύπο

Εμβόλιο της Pfizer για τη Νόσο covid-19 και αλλεργίες.

<< < (3/3)

Argirios Argiriou:
Σχετική ανακοίνωση της Ελληνικής Εταιρείας Αλλεργιολογίας και Κλινικής Ανοσολογίας στις 21/12/2020.

Επισυνάπτεται.

Πατρωνάκης Μάνος:
 Αναθεωρημένο (23/12) εκπαιδευτικό εγχειρίδιο για τα εμβολιαστικά κέντρα.

Argirios Argiriou:

Management of anaphylaxis at a COVID-19 vaccination site
If anaphylaxis is suspected, take the following steps:

Rapidly assess airway, breathing, circulation, and mentation (mental activity).
Call for emergency medical services.
Place the patient in a supine position (face up), with feet elevated, unless upper airway obstruction is present or the patient is vomiting.
Epinephrine (1 mg/ml aqueous solution [1:1000 dilution]) is the first-line treatment for anaphylaxis and should be administered immediately.
In adults, administer a 0.3 mg intramuscular dose using a premeasured or prefilled syringe, or an autoinjector in the mid-outer thigh.
The maximum adult dose is 0.5 mg per dose.
Epinephrine dose may be repeated every 5-15 minutes (or earlier) as needed to control symptoms while waiting for emergency medical services.
Because of the acute, life-threatening nature of anaphylaxis, there are no contraindications to epinephrine administration.
Antihistamines (e.g., H1 or H2 antihistamines) and bronchodilators do not treat airway obstruction or hypotension, and thus are not first-line treatments for anaphylaxis. However, they can help provide relief for hives and itching (antihistamines) or symptoms of respiratory distress (bronchodilators) but should only be administered after epinephrine in a patient with anaphylaxis. Because anaphylaxis may recur after patients begin to recover, monitoring in a medical facility for several hours is advised, even after complete resolution of symptoms and signs.

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

Πλοήγηση

[0] Λίστα μηνυμάτων

[*] Προηγούμενη σελίδα